Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Jun 20;39(18):2016-2024.
doi: 10.1200/JCO.20.02880. Epub 2021 Apr 23.

Association of Germline BRCA Pathogenic Variants With Diminished Ovarian Reserve: A Meta-Analysis of Individual Patient-Level Data

Affiliations
Meta-Analysis

Association of Germline BRCA Pathogenic Variants With Diminished Ovarian Reserve: A Meta-Analysis of Individual Patient-Level Data

Volkan Turan et al. J Clin Oncol. .

Abstract

Purpose: To determine whether germline BRCA (gBRCA) pathogenic variants are associated with decreased ovarian reserve.

Materials and methods: An individual patient-level data meta-analysis was performed using five data sets on 828 evaluable women who were tested for gBRCA. Of those, 250 carried gBRCA, whereas 578 had tested negative and served as controls. Of the women with gBRCA, four centers studied those affected with breast cancer (n = 161) and one studied unaffected individuals (n = 89). The data were adjusted for the center, age, body mass index, smoking, and oral contraceptive pill use before the final analysis. Anti-Müllerian hormone (AMH) levels in affected women were drawn before presystemic therapy.

Results: The mean age of women with versus without gBRCA1/2 (34.1 ± 4.9 v 34.3 ± 4.8 years; P = .48) and with gBRCA1 versus gBRCA2 (33.7 ± 4.9 v 34.6 ± 4.8 years; P = .16) was similar. After the adjustments, women with gBRCA1/2 had significantly lower AMH levels compared with controls (23% lower; 95% CI, 4 to 38; P = .02). When the adjusted analysis was limited to affected women (157 with gBRCA v 524 without, after exclusions), the difference persisted (25% lower; 95% CI, 9 to 38; P = .003). The serum AMH levels were lower in women with gBRCA1 (33% lower; 95% CI, 12 to 49; P = .004) but not gBRCA2 compared with controls (7% lower; 95% CI, 31% lower to 26% higher; P = .64).

Conclusion: Young women with gBRCA pathogenic variants, particularly those affected and with gBRCA1, have lower serum AMH levels compared with controls. They may need to be preferentially counseled about the possibility of shortened reproductive lifespan because of diminished ovarian reserve.

PubMed Disclaimer

Conflict of interest statement

Matteo LambertiniConsulting or Advisory Role: Roche, Novartis, Lilly, AstraZenecaSpeakers' Bureau: Theramex, Takeda, Roche, Lilly, Novartis, Pfizer, Sandoz Erica WangConsulting or Advisory Role: OncoPepResearch Funding: Merck Florian ClatotHonoraria: Merck Serono, Bristol-Myers Squibb, AstraZenecaConsulting or Advisory Role: Lilly, Bristol-Myers Squibb, Roche, Merck SeronoResearch Funding: AstraZeneca, Roche DiagnosticsTravel, Accommodations, Expenses: Merck Serono, Roche, Bristol-Myers Squibb Beth Y. KarlanConsulting or Advisory Role: Roche Pharma AG, Merck, Mercy BioAnalyticsResearch Funding: VBL Therapeutics, AstraZenecaPatents, Royalties, Other Intellectual Property: US and EU patent on gene signatureOther Relationship: Elsevier Isabelle DemeestereConsulting or Advisory Role: RocheResearch Funding: Roche DiagnosticsTravel, Accommodations, Expenses: FerringNo other potential conflicts of interest were reported.

Figures

FIG 1.
FIG 1.
Study inclusion and exclusion flowchart.
FIG 2.
FIG 2.
AMH values by BRCA. Forest plot analysis of individual results from five participating centers. One is null value of 0 difference or decrease. Individual centers were minimally adjusted, whereas overall data were adjusted for center, age, smoking, OCP, and BMI. AMH, anti-Müllerian hormone; BMI, body mass index; OCP, oral contraceptive pills.

References

    1. Venkitaraman AR.Beyond cancer genomics: After the end of the beginning Curr Opin Genet Dev 221–22012 - PubMed
    1. Rebbeck TR, Mitra N, Wan F, et al. The CIMBA Consortium Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer JAMA 3131347–13612015 - PMC - PubMed
    1. Oktay K, Kim JY, Barad D, et al. Association of BRCA1 mutations with occult primary ovarian insufficiency: A possible explanation for the link between infertility and breast/ovarian cancer risks J Clin Oncol 28240–2442010 - PMC - PubMed
    1. Turan V, Bedoschi G, Emirdar V, et al. Ovarian stimulation in patients with cancer: Impact of letrozole and BRCA mutations on fertility preservation cycle outcomes Reprod Sci 2526–322018 - PubMed
    1. Titus S, Li F, Stobezki R, et al. Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Sci Transl Med. 2013;5:172ra21. - PMC - PubMed

Publication types